Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody

被引：95
|
作者：
Yoshizaki, K
Nishimoto, N
Mihara, M
Kishimoto, T
机构：
[1] Osaka Univ, Sch hlth & Sports Sci, Dept Med Sci 1, Suita, Osaka 5650871, Japan
[2] Chugai Pharmaceut Co Ltd, Fuji Gotenba Labs, Shizuoka, Japan
来源：
SPRINGER SEMINARS IN IMMUNOPATHOLOGY | 1998年 / 20卷 / 1-2期
关键词：
D O I：
10.1007/s002810050033
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：247 / 259
页数：13
相关论文
共 50 条
  • [1] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Kazuyuki Yoshizaki
    Norihiro Nishimoto
    Masahiro Mihara
    Tadamitsu Kishimoto
    Springer Seminars in Immunopathology, 1998, 20 : 247 - 259
  • [2] Increase in serum levels of IL-6 and soluble IL-6 receptor after anti-IL-6 receptor antibody therapy in patients with rheumatoid arthritis
    Nishimoto, N
    Terao, K
    Kakehi, T
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S109 - S110
  • [3] Tocilizumab - A humanized anti-IL-6 receptor monoclonal antibody for the treatment of rheumatoid arthritis
    Schlesselman, Lauren S.
    Hussey, Aaron P.
    FORMULARY, 2008, 43 (08) : 272 - 279
  • [4] Alleviation of systemic manifestations of Castleman's disease by blockade of IL-6 signal transduction with humanized anti-IL-6 receptor antibody.
    Nishimoto, N
    Sasai, M
    Shima, Y
    Danno, N
    Yoshizaki, K
    Kishimoto, T
    BLOOD, 1996, 88 (10) : 1243 - 1243
  • [5] The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis
    Ohsugi, Yoshiyuki
    Kishimoto, Tadamitsu
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (05) : 669 - 681
  • [6] Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
    Yoshizaki, K
    Nishimoto, N
    Miyasaka, N
    Yamamoto, K
    Kawai, S
    Takeuchi, T
    Kishimoto, T
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S42 - S42
  • [7] Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
    K Yoshizaki
    N Nishimoto
    N Miyasaka
    K Yamamoto
    S Kawai
    T Takeuchi
    T Kishimoto
    Arthritis Res Ther, 5
  • [8] A New Therapeutic Strategy for Autoimmune and Chronic Inflammatory Disease Based on Clinical Results Using IL-6 Blocking Therapy with a Humanized Anti-IL-6 Receptor Antibody
    Yoshizaki, Kazuyuki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2009, 129 (06): : 667 - 674
  • [9] Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis
    Hashimoto, Motomu
    Fujii, Takao
    Hamaguchi, Masahide
    Furu, Moritoshi
    Ito, Hiromu
    Terao, Chikashi
    Yamamoto, Keiichi
    Yamamoto, Wataru
    Matsuo, Takashi
    Mori, Masato
    Ohmura, Koichiro
    Kawabata, Hiroshi
    Mimori, Tsuneyo
    PLOS ONE, 2014, 9 (05):
  • [10] BLOCKING INTERLEUKIN-6 (IL-6) BY AN ANTI-INTERLEUKIN-6 RECEPTOR (IL-6R) MONOCLONAL ANTIBODY IN RHEUMATOID ARTHRITIS (RA)
    Choy, E. H. S.
    Isenberg, D. A.
    Garrood, T.
    Farrow, S.
    Ioannou, Y.
    Bird, H.
    Cheung, N.
    Williams, B. D.
    Hazleman, B.
    Price, R.
    Kishimoto, T.
    Panayi, G. S.
    RHEUMATOLOGY, 2002, 41 : 15 - 15
12345